MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 561786 | Name: Tegoprazan
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tegoprazan is a potassium-competitive acid blocker that controls gastric acid secretion and motility. Tegoprazan works by inhibiting the H+/K+ transporter (ATP4A), also known as the gastric proton pump, in the stomach lining. This reduces the secretion of gastric acid. According to a study, tegoprazan has stronger and more reversible gastric acid suppression than traditional PPIs. Another study says that tegoprazan is associated with lower hepatotoxicity than other PPIs. .

Chemical Structure

Tegoprazan
Tegoprazan
CAS#942195-55-3

Theoretical Analysis

MedKoo Cat#: 561786

Name: Tegoprazan

CAS#: 942195-55-3

Chemical Formula: C20H19F2N3O3

Exact Mass: 387.1394

Molecular Weight: 387.38

Elemental Analysis: C, 62.01; H, 4.94; F, 9.81; N, 10.85; O, 12.39

Price and Availability

Size Price Availability Quantity
5mg USD 550.00 2 Weeks
10mg USD 950.00 2 Weeks
25mg USD 1,650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Tegoprazan; CJ-12420; CJ 12420; CJ12420; RQ-00000004; RQ00000004; RQ 00000004;
IUPAC/Chemical Name
(S)-4-((5,7-Difluorochroman-4-yl)oxy)-N,N,2-trimethyl-1H-benzo[d]imidazole-6-carboxamide
InChi Key
CLIQCDHNPDMGSL-HNNXBMFYSA-N
InChi Code
InChI=1S/C20H19F2N3O3/c1-10-23-14-6-11(20(26)25(2)3)7-17(19(14)24-10)28-15-4-5-27-16-9-12(21)8-13(22)18(15)16/h6-9,15H,4-5H2,1-3H3,(H,23,24)/t15-/m0/s1
SMILES Code
O=C(C1=CC(O[C@H]2CCOC3=C2C(F)=CC(F)=C3)=C4C(NC(C)=N4)=C1)N(C)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Tegoprazan (CJ-12420) is a fast-acting, oral , potassium-competitive acid blocker (P-CAB). It's used to treat acid-related gastrointestinal diseases , such as peptic ulcers and gastroesophageal reflux disease (GERD).
Solvent mg/mL mM
Solubility
Soluble in DMSO 0.0 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 387.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Tietto A, Faggin S, Scarpignato C, Savarino EV, Giron MC. Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Expert Opin Drug Metab Toxicol. 2024 Aug 27. doi: 10.1080/17425255.2024.2397433. Epub ahead of print. PMID: 39189409. 2: Jung BW, Park CH, Jung YS. Efficacy and safety of tegoprazan- and rabeprazole-based concomitant therapies for Helicobacter pylori infection: Real- world evidence. J Gastroenterol Hepatol. 2024 Aug 26. doi: 10.1111/jgh.16719. Epub ahead of print. PMID: 39188111. 3: Scarpignato C, Hunt RH. Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments. Curr Gastroenterol Rep. 2024 Nov;26(11):273-293. doi: 10.1007/s11894-024-00939-3. Epub 2024 Aug 15. PMID: 39145848; PMCID: PMC11401795. 4: Wu B, Xiao M, Wu F, Xu T. Signal of dementia with proton pump inhibitor after minimizing competition bias: an updated disproportionality analysis. Expert Opin Drug Saf. 2024 Aug 5:1-8. doi: 10.1080/14740338.2024.2387314. Epub ahead of print. PMID: 39082094. 5: Kim HS, Choi YK, Oh M, Cho YS, Ghim JL. Enhancing drug administration flexibility: evaluation of pharmacokinetic properties of tegoprazan orally disintegrating tablet (ODT) administered via nasogastric tube or oral dosing. Transl Clin Pharmacol. 2024 Jun;32(2):98-106. doi: 10.12793/tcp.2024.32.e9. Epub 2024 Jun 26. PMID: 38974342; PMCID: PMC11224899. 6: Ouyang M, Zou S, Cheng Q, Shi X, Zhao Y, Sun M. Comparative Efficacy and Safety of Potassium-Competitive Acid Blockers vs. Proton Pump Inhibitors for Peptic Ulcer with or without Helicobacter pylori Infection: A Systematic Review and Network Meta-Analysis. Pharmaceuticals (Basel). 2024 May 28;17(6):698. doi: 10.3390/ph17060698. PMID: 38931366; PMCID: PMC11206580. 7: Xue C, Du Y, Yang H, Jin H, Zhao Y, Ren B, Dong Z. Evaluating vonoprazan and tegoprazan for gastroesophageal reflux disease treatment in Chinese Healthcare: an EVIDEM framework analysis. BMC Gastroenterol. 2024 Jun 20;24(1):208. doi: 10.1186/s12876-024-03297-6. PMID: 38902604; PMCID: PMC11188247. 8: Kong Q, Mirza IA, Zhang X, Song X, Li X, Zhang Q, Xu L, Guo Y, Yu Y, Zuo X, Li Y, Li Y. Fourteen-Day Tegoprazan-Amoxicillin Dual Therapy as the First-Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial. Helicobacter. 2024 May- Jun;29(3):e13098. doi: 10.1111/hel.13098. PMID: 38853394. 9: Jiang Y, Zhang R, Fang Y, Zhao R, Fu Y, Ren P, Zhan Q, Shao M. P-CAB versus PPI in the eradication of Helicobacter pylori: a systematic review and network meta-analysis. Therap Adv Gastroenterol. 2024 May 14;17:17562848241241223. doi: 10.1177/17562848241241223. PMID: 38751605; PMCID: PMC11095192. 10: Huh CW, Youn YH, Jung DH, Cha RR, Kim YJ, Jung K, Song KH, Bang KB, Tae CH, Choi SI, Shin CM; Functional Dyspepsia Research Group Under the Korean Society of Neurogastroenterology and Motility. Efficacy of Tegoprazan in Patients With Functional Dyspepsia: A Prospective, Multicenter, Single-arm Study. J Neurogastroenterol Motil. 2024 Jul 30;30(3):313-321. doi: 10.5056/jnm23150. Epub 2024 May 4. PMID: 38710534; PMCID: PMC11238105. 11: Zheng H, Yuan S, Liu J. Efficacy and safety of tegoprazan in the treatment of gastroesophageal reflux disease: A protocol for meta-analysis and systematic review. PLoS One. 2024 May 2;19(5):e0302450. doi: 10.1371/journal.pone.0302450. PMID: 38696509; PMCID: PMC11065240. 12: Du Y, Yu L, Deng B, Li Q, Hu J, Li L, Xu Y, Song L, Xie F, Wang Y, Chen Y, Liu C, Zhai X, Lu Y. Pharmacokinetic Interactions Between Tegoprazan and the Combination of Clarithromycin, Amoxicillin and Bismuth in Healthy Chinese Subjects: An Open-Label, Single-Center, Multiple-Dosage, Self-Controlled, Phase I Trial. Clin Drug Investig. 2024 May;44(5):343-355. doi: 10.1007/s40261-024-01359-x. Epub 2024 Apr 13. PMID: 38615091. 13: Kanu JE, Soldera J. Treatment of Helicobacter pylori with potassium competitive acid blockers: A systematic review and meta-analysis. World J Gastroenterol. 2024 Mar 7;30(9):1213-1223. doi: 10.3748/wjg.v30.i9.1213. PMID: 38577188; PMCID: PMC10989498. 14: Liu HN, Wang R, Cao Y, Xian F, Bi XJ, Wu DJ, Wang B, Wang XW, Lan CH. Comparison of the Efficacy Between the Dual Therapy of Tegoprazan and the Quadruple Therapy of Tegoprazan: A Randomized Controlled Multicenter Study. Clin Transl Gastroenterol. 2024 Apr 1. doi: 10.14309/ctg.0000000000000699. Epub ahead of print. PMID: 38557975. 15: Cho JH. Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line Helicobacter pylori eradication: a real- world evidence study. Expert Rev Anti Infect Ther. 2024 Mar 13:1-7. doi: 10.1080/14787210.2024.2329251. Epub ahead of print. PMID: 38459869. 16: Kim BW, Park JJ, Moon HS, Lee WS, Shim KN, Baik GH, Lim YJ, Lee HL, Youn YH, Park JC, Sung IK, Chung H, Moon JS, Kim GH, Hong SJ, Choi HS. The Effect of Tegoprazan on the Treatment of Endoscopic Resection-Induced Artificial Ulcers: A Multicenter, Randomized, Active-Controlled Study. Gut Liver. 2024 Mar 15;18(2):257-264. doi: 10.5009/gnl230242. Epub 2024 Feb 22. PMID: 38384180; PMCID: PMC10938149. 17: Zhuang Q, Chen S, Zhou X, Jia X, Zhang M, Tan N, Chen F, Zhang Z, Hu J, Xiao Y. Comparative Efficacy of P-CAB vs Proton Pump Inhibitors for Grade C/D Esophagitis: A Systematic Review and Network Meta-analysis. Am J Gastroenterol. 2024 May 1;119(5):803-813. doi: 10.14309/ajg.0000000000002714. Epub 2024 Feb 12. PMID: 38345252. 18: Dong Y, Xu H, Zhang Z, Zhou Z, Zhang Q. Comparative efficiency and safety of potassium competitive acid blockers versus Lansoprazole in peptic ulcer: a systematic review and meta-analysis. Front Pharmacol. 2024 Jan 11;14:1304552. doi: 10.3389/fphar.2023.1304552. PMID: 38273830; PMCID: PMC10808560. 19: Oh CK, Lim H, Seo SI, Lee SP, Bang CS, Shin WG, Kim JB, Jang HJ, Baik GH. Efficacy comparison of 7- and 14-day P-CAB based bismuth-containing quadruple regimen with PPI based bismuth-containing quadruple regimen for Helicobacter pylori infection: rationale and design of an open-label, multicenter, randomized controlled trial. BMC Gastroenterol. 2023 Dec 21;23(1):453. doi: 10.1186/s12876-023-03100-y. PMID: 38129806; PMCID: PMC10734161. 20: Buzás GM. A káliumkompetitív savgátlók szerepe a felső emésztőtraktus savfüggő betegségeinek kezelésében [The role of potassium-competitive acid blockers in the treatment of acid-related digestive diseases]. Orv Hetil. 2023 Dec 17;164(50):1967-1973. Hungarian. doi: 10.1556/650.2023.32937. PMID: 38108833.

View History

AT-076

AT-076

Enpiperate

Enpiperate

Fluoresone

Fluoresone